Given the results from the BILCAP trial presented at ASCO, would you change to or initiate therapy with capecitabine for patients with biliary tract cancer in the post-operative setting?

The BILCAP study represents the first data from a large, randomized, prospective, adequately-powered trial demonstrating a survival benefit for adjuvant therapy in this difficult-to-treat and relatively rare cancer.

Given that capecitabine is relatively well tolerated, I would likely change from gemc...